ReviewInternational journal of chronic obstructive pulmonary disease2009
Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.
Review in International journal of chronic obstructive pulmonary disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02234739 (Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective，Open Cohort Study (VIA-COPD)
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Beyond the Norm: Atypical Manifestations of Aspergillosis.Respirology case reports · 2026Article
- Invasive fungal infections and the management in immunocompromised conditions.Journal of family medicine and primary care · 2025Review
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- IFN Receptor 2 Regulates TNF-α-Mediated Damaging Inflammation during Aspergillus Pulmonary Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Review
- Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents.ACS omega · 2023Article
- Aspergillus infection in chronic obstructive pulmonary diseases.The clinical respiratory journal · 2023Review
- Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.European journal of clinical pharmacology · 2017Article
- Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia.BMC pulmonary medicine · 2017Article
- Clinical Application of High-Resolution Computed Tomographic Imaging Features of Community-Acquired Pneumonia.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Article
- Bacterial Adaptation during Chronic Respiratory Infections.Pathogens (Basel, Switzerland) · 2015Review
- Invasive pulmonary aspergillosis accompanied by soft tissue lesions during treatment of a patient with hyperthyroidism: a case report.Central-European journal of immunology · 2015Article
- Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study.Respiratory research · 2014Article
- Invasive Aspergillus infections in hospitalized patients with chronic lung disease.Infection and drug resistance · 2013Article
- Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease.Current infectious disease reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in patients with hematologic malignancies. The reported incidence of IPA in the context of chronic obstructive pulmonary disease (COPD) seems to increase. Approximately 1%-2% of overall fatal cases of IPA occur in COPD patients. The combination of factors such as lung immune imbalance, long-term corticosteroid use, increasing rate of bacterial exacerbations over time, and malnutrition are responsible for the emergence of IPA in these patients. The diagnosis of IPA is difficult to establish, which explains the delay in implementing accurate antifungal therapy and the high mortality rate. Persistent pneumonia nonresponsive to appropriate antibiotic treatment raises the concern of an invasive fungal infection. Definite diagnosis is obtained from tissue biopsy evidencing Aspergillus spp. on microscopic examination or in culture. Culture and microscopy of respiratory tract samples have a sensitivity and specificity of around 50%. Other diagnostic tools can be useful in documenting IPA: computed tomography (CT) scan, nonculture-based tests in serum and/or in bronchoalveolar lavage such as antibody/antigen tests for Aspergillus spp. More recent tools such as polymerase chain reaction or [1-->3]-beta-D-glucan have predictive values that need to be further investigated in COPD patients. Antifungal monotherapy using azole voriconazole is recommended as a first-line treatment of IPA. This review assesses the use of voriconazole in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.